Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-12 of 38 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-12 of 38 studies
-
Genetic TherapyClosed to Enrollment
Study to evaluate VX-522 in adults 18 years and older with cystic fibrosis. , protocol number Vertex VX21-522-001 SADThis study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA) therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy.
-
Age:
18 Years to 65 Years
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
6 months
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of VX-121/tezacaftor/deutivacaftor in?children ages 6 to 11 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort B1This study is taking place at multiple care centers across the U.S. It will look at safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
60% or greater
-
Number of Visits:
8
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of VX-121/tezacaftor/deutivacaftor in children ages 6 to 11 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort A1This study is taking place at multiple care centers across the U.S. It will look at safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
60% or greater
-
Number of Visits:
8
-
Length of Participation:
7 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Study of ELX-02 in adults with cystic fibrosis who have at least one nonsense mutation. , protocol number Eloxx EL-012 - Treatment Period 5, 6 and 7 (Kalydeco or Trikafta)This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X or similar nonsense mutation.
-
Age:
18 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
9 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Study of Trikafta® in people with CF ages 12 years and older who have partial function CFTR mutations , protocol number Sorscher Partial Function Sub-StudyThis study will look at the effectiveness of Trikafta®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and evidence of partial CFTR function. Partial function is defined as a sweat chloride level < 80 mmol/L and/or pancreatic sufficiency (no pancreatic enzyme supplement therapy).
-
Age:
12 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
2 months
-
-
Restore CFTR ProteinClosed to Enrollment
Study of Trikafta® in people with CF ages 12 years and older who have an N1303K CFTR mutation , protocol number N1303K Sub-StudyThis study will look at the effectiveness of Trikafta, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and a least one of these mutations must be N1303K.
-
Age:
12 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
86 days
-
-
Restore CFTR ProteinClosed to Enrollment
Study of VX-121 in people with CF ages 12 years and older who have either two copies of the F508del mutation, one copy of the F508del mutation and one copy of a gating or residual function mutation, or no copies of the F508del mutation and at least one other triple combination responsive CFTR mutation , protocol number Vertex VX20-121-103This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal.
-
Age:
12 Years and Older
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
64 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number Eloxx EL-012 - Cohorts 1 to 4This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X mutation.
-
Age:
18 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
15
-
Length of Participation:
15 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion) , protocol number Translate Bio MRT5005-101This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
50 to 90%
-
Number of Visits:
21
-
Length of Participation:
1 years
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX-770-126This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.
-
Age:
Less than 25 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
18
-
Length of Participation:
128 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX15-770-124This two-part, open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.
-
Age:
Less than 13 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
SNO7: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
12 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More